...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in hematology >Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: Indications and outcomes
【24h】

Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: Indications and outcomes

机译：异种造血细胞移植惰性非霍奇金淋巴瘤：适应症和结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: Allogeneic hematopoietic cell transplantation (HCT) can potentially cure indolent non-Hodgkin lymphoma (NHL). However, the optimal timing and indications remain unclear. Here, we review recent published reports on the subject and summarize our approach. RECENT FINDINGS: Recent prospective clinical trials of allogeneic HCT in indolent NHL are marked by substantial variation in eligibility criteria, patient populations, and transplant approach. Nonetheless, several common themes are apparent. Indolent NHL is highly susceptible to immunologic graft-versus-lymphoma effects and relapse rates after allogeneic HCT are uniformly low. Allogeneic HCT early in the disease course produces the highest overall and progression-free survival, but also increases patient exposure to potential transplant-related complications such as chronic graft-versus-host disease. In contrast, allogeneic HCT can be reserved as a 'last resort' for patients who are refractory to conventional chemotherapy, delaying their exposure to graft-versus-host disease and other transplant-associated risks. No trials have directly addressed the optimal timing of allogeneic HCT in indolent NHL nor prospectively compared different transplant approaches. SUMMARY: Excellent outcomes have been reported with allogeneic HCT for indolent NHL, both early and late in the disease course. The optimal timing of allogeneic HCT is unknown and depends heavily on patient preferences.
机译：审查目的：同种异体造血细胞移植（HCT）可以潜在地固化惰性非霍奇金淋巴瘤（NHL）。然而，最佳定时和适应症仍然不清楚。在这里，我们审查了最近关于该主题的报告并总结了我们的方法。最近的发现：惰性NHL中的同种异体HCT的最近前瞻性临床试验标志着资格标准，患者群体和移植方法的实质性变化。尽管如此，几个常见的主题是明显的。惰性NHL高易受免疫接枝 - 与淋巴瘤的影响和异种HCT均匀低的复发率。在疾病课程早期的同种异体HCT产生最高的总体和无进展的存活，而且还增加了患者暴露于潜在的移植相关的并发症，如慢性接枝与宿主疾病。相比之下，同种异体的HCT可以保留作为难以常规化疗的难治性的患者的“最后的度假胜地”，延迟暴露于移植物与宿主疾病和其他移植相关风险的患者。没有试验直接解决了惰性NHL中同种异体HCT的最佳时间，也不会对比较不同的移植方法。发明内容：在疾病课程早期和晚期，对异种NHL进行了同种异体HCT的出色结果。同种异体HCT的最佳定时未知，并且依赖于患者偏好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号